


Renal Denervation: A Practical Guide for Health Professionals

Managing Hypertension

Roland Schmider, Michel Burnier, Cara East, Konstantinos Tsioufis, Sean Delaney

Supplementary Material


Supplementary Figure 1: Systolic BP changes from Baseline to 36 Months (SPYRAL-HTN ON MEDS)



SPB = systolic BP

Source: Mahfoud et al. 2022.¹ Reproduced with permission from Elsevier.

Supplementary Figure 2: Change in Ambulatory BP from Baseline to 2 Months in the Intention-to-Treat Population (RADIANCE-HTN SOLO)




CI = confidence interval

Source: Aziz et al. 2018.² Reproduced with permission from Elsevier.

Supplementary Figure 3: 24-h Ambulatory Profiles of Systolic BP at Baseline and 2 Months in the Renal Denervation Group and the Sham Group in the Intention-to-Treat Population

Between baseline and 2 months, 64 (93%) of 69 patients in the renal denervation group and 57 (85%) of 67 patients in the sham procedure group had no change in their baseline antihypertensive treatment. Error bars represent standard errors (RADIANCE-HTN TRIO)



IQR = interquartile range

Source: Aziz et al. 2021.³ Reproduced with permission from Elsevier.

References

1. Mahfoud F, Kandazari DE, Kario K, et al. Long-term efficacy and safety of renal denervation in the presence of antihypertensive drugs (SPYRAL HTN-ON MED): a randomised, sham-controlled trial. *Lancet* 2022;399:1401–10.
[https://doi.org/10.1016/S0140-6736\(22\)00455-X](https://doi.org/10.1016/S0140-6736(22)00455-X); PMID: 35390320.
2. Azizi M, Schmieder RE, Mahfoud F, et al. Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. *Lancet* 2018;391:2335–45.
[https://doi.org/10.1016/S0140-6736\(18\)31082-1](https://doi.org/10.1016/S0140-6736(18)31082-1); PMID: 29803590.
3. Azizi M, Sanghvi K, Saxena M, et al. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN Trio): a randomised, multicentre, single-blind, sham-controlled trial. *Lancet* 2021;397:2476–86.
[https://doi.org/10.1016/S0140-6736\(21\)00788-1](https://doi.org/10.1016/S0140-6736(21)00788-1); PMID: 34010611.